Table S1.

PICOS approach and inclusion criteria

Population	Men with localized (T1–T2, N0–Nx, M0) and locally advanced (T3–T4, N0–Nx, M0) prostate cancer
Intervention	SBRT monotherapy, defined as a single 6–15 Gy fraction lasting up to 45 minutes per day, for a total of up to five treatments, over approximately 2 weeks, either on a robotic arm or a gantry LINAC
Control	Either no control group (ie, single-arm study) or a multiarm study that may also contain the intervention
Outcomes
Efficacy	Clinical (surrogate outcomes) for all studies: PSA kinetics, FFBF as defined by ASTRO or Phoenix definitions
Safety	Late RTOG or CTCAE GU, GI toxicities
Study design
Efficacy	All prospective and retrospective studies, ≥25 patients, with one or more arms, >30-month FU
Safety	All prospective and retrospective studies, ≥25 patients, with one or more arms, >30-month FU

Abbreviations: ASTRO, American Society of Therapeutic Radiology and Oncology; CTCAE, Common Terminology Criteria for Adverse Events; FFBF, freedom from biochemical failure; FU, follow-up; GI, gastrointestinal; GU, genitourinary; LINAC, linear accelerator; PICOS, population, intervention, control, outcome, study design; PSA, prostate-specific antigen; RTOG, Radiation Therapy Oncology Group; SBRT, stereotactic body radiation therapy.